ISOVUE-M 300 Drug Patent Profile

✉ Email this page to a colleague

When do Isovue-m 300 patents expire, and when can generic versions of Isovue-m 300 launch?

Isovue-m 300 is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in ISOVUE-M 300 is iopamidol. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iopamidol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Isovue-m 300

A generic version of ISOVUE-M 300 was approved as iopamidol by HAINAN POLY on February 27^th, 2023.

Try a Trial

Summary for ISOVUE-M 300

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	20
Patent Applications:	3,887
Formulation / Manufacturing:	see details
DailyMed Link:	ISOVUE-M 300 at DailyMed

Drug patent expirations by year for ISOVUE-M 300

Recent Clinical Trials for ISOVUE-M 300

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NYU Langone Health	N/A
M.D. Anderson Cancer Center	N/A
National Cancer Institute (NCI)	N/A

See all ISOVUE-M 300 clinical trials

Pharmacology for ISOVUE-M 300

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

Anatomical Therapeutic Chemical (ATC) Classes for ISOVUE-M 300

V08AB	Watersoluble, nephrotropic, low osmolar X-ray contrast media
V08A	X-RAY CONTRAST MEDIA, IODINATED
V08	CONTRAST MEDIA
V	Various

US Patents and Regulatory Information for ISOVUE-M 300

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	ISOVUE-M 300	iopamidol	INJECTABLE;INJECTION	018735-004	Dec 31, 1985	AP	RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ISOVUE-M 300

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	ISOVUE-M 300	iopamidol	INJECTABLE;INJECTION	018735-004	Dec 31, 1985	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ISOVUE-M 300

See the table below for patents covering ISOVUE-M 300 around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Sweden	7514076		⤷ Try a Trial
Croatia	P931221	PROCESS FOR THE PREPARATION OF BIS-(DIHYDROXYPROPYLAMIDE) 5-HIDROXY-PROPYLAMINO-2,4,6-TRIIOD-ISOPHTALIC ACID	⤷ Try a Trial
Slovenia	7513155	PROCESS FOR PREPARING BIS-(DIHYDROXY-PROPYL)-AMIDES OF 5-HYDROXY-PROPIONYLAMINO-2,4,6-TRIIODO-ISOPHTHALIC ACID, WHICH ARE EASILY SOLUBLE IN WATER	⤷ Try a Trial
Netherlands	157295		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for ISOVUE-M 300

Recent Clinical Trials for ISOVUE-M 300

Pharmacology for ISOVUE-M 300

Anatomical Therapeutic Chemical (ATC) Classes for ISOVUE-M 300

Make Better Decisions: Try a trial or see plans & pricing